Liver injury in COVID-19: The current evidence
Saleh A Alqahtani, Jörn M Schattenberg, Saleh A Alqahtani, Jörn M Schattenberg
Abstract
Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. In the context of COVID-19, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of COVID-19, direct effect of the virus, or a complicated disease course. Recent studies proposed several theories on potential mechanisms of liver injury in these patients. This review summarizes current evidence related to hepatobiliary complications in COVID-19, provides an overview of the available case series and critically elucidates the proposed mechanisms and provides recommendations for clinicians.
Keywords: COVID-19; SARS-CoV2; cholangiocytes; cytokine storm; liver function test; liver injury; lymphopenia.
Figures
References
- Yang Z, Xu M, Yi JQ, et al. Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int 2005; 4: 60–63.
- Farcas GA, Poutanen SM, Mazzulli T, et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005; 191: 193–197.
- Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420--422.
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271--280.e8.
- Liu F, Long X, Zou W, et al. Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection. medrxiv Preprint 3 March 2020: 2020.2002. 2028.20029181. DOI: 10.1101/2020.02.28.20029181.
- Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv Preprint 4 February 2020: 2020.2002.2003.931766. DOI: 10.1101/2020.02. 03.931766.
- Fan Z, Chen L, Li J, et al. Clinical Features of COVID-19 related liver damage. medRxiv Preprint 28 February 2020: 2020.2002.2026.20026971. DOI: 10.1101/2020.02.26.20026971.
- Zhang C, Shi L, Wang FS. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 2020; 5: 428--430.
- Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int Epub ahead of print 14 March 2020. DOI: 10.1111/liv.14435.
- Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver organoids. biorxiv Preprint 17 March 2020: 2020.2003.2016.990317. DOI: 10.1101/2020.03.16. 990317.
- Li L, Li S, Xu M, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv Preprint 10 March 2020: 2020.2002. 2028.20028514. DOI: 10.1101/2020.02.28.20028514.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
- Cui Y, Tian M, Huang D, et al. A 55-day-old female infant infected with COVID 19: Presenting with pneumonia, liver injury, and heart damage. J Infect Dis Epub ahead of print 17 March 2020. DOI: 10.1093/infdis/jiaa113.
- Shi Y, Wang Y, Shao C, et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ 2020; 27: 1451--1454.
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.
- McDonald B, Kubes P. Innate immune cell trafficking and function during sterile inflammation of the liver. Gastroenterology 2016; 151: 1087–1095.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507–513.
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. Epub ahead of print 24 February 2020. DOI: 10.1016/S2213-2600(20)30079-5.
- Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv Preprint 27 February 2020: 2020.2002.2026.20028191. DOI: 10.1101/2020.02.26.20028191.
- Yang Y, Lu Q, Liu M, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv Preprint 21 February 2020: 2020.2002. 2010.20021675. DOI: 10.1101/2020.02.10.20021675.
- Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ 2020; 368: m606.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069.
- Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Diss 2020; 20: 425–434.
- Huang Y, Yang R, Xu Y, et al. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv Preprint 5 March 2020: 2020.2002.2027. 20029009. DOI: 10.1101/2020.02.27.20029009.
- Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. Epub ahead of print 28 February 2020. DOI: 10.1056/NEJMoa2002032.
- Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. medRxiv Preprint 19 February 2020: 2020.2002. 2017.20024018. DOI: 10.1101/2020.02.17.20024018.
- Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv Preprint 25 February 2020: 2020.2002.2023.20026963. DOI: 10.1101/2020.02.23.20026963.
- Bangash MN, Patel J, Parekh D. COVID-19 and the liver: Little cause for concern. Lancet Gastroenterol Hepatol 2020. Epub ahead of print 20 March 2020. DOI: 10.1016/S2468-1253(20)30084-4.
- Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology 2020. Epub ahead of print 27 March 2020. DOI: 10.1002/hep.31257.
- Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury. A retrospective study. Liver Int 2020. Epub ahead of print 2 April 2020. DOI: 10.1111/liv.14449.
- Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020. Epub ahead of print 2 April 2020. DOI: 10.1111/liv.14455.
- Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020. Epub ahead of print 20 March 2020. DOI: 10.1002/jmv.25781.
- Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020. Epub ahead of print 12 March 2020. DOI: 10.1093/cid/ciaa247.
- Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020; 8: 18–24.
- Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet 2020; 395: 809–815.
- Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology Epub ahead of print 13 February 2020; DOI: 10.1148/radiol.2020200370.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tocilizumab. [Updated 18 June 2015]. Available from: [Accessed: 2 April 2020].
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020: 101623.
- Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10: 818–824.
- Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol 2006; 168: 1057–1059.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med Epub ahead of print 18 Mar 2020. DOI: 10.1056/NEJMoa2001282.
- Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72–73.
- Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020; 15: 247--249.
- De Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117: 6771–6776.
- Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003; 361: 1767–1772.
- Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020. DOI: 10.1016/j.jhepr.2020.100113.
Source: PubMed